Trial of Neoadjuvant Trastuzumab Emtansine in Patients With HER2-Equivocal Breast Cancer
Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 25 Oct 2016
At a glance
- Drugs Trastuzumab emtansine (Primary)
- Indications Breast cancer
- Focus Therapeutic Use
- Acronyms NATURE
- 07 Jun 2017 Biomarkers information updated
- 22 Jun 2016 Planned End Date changed from 1 Apr 2019 to 1 May 2019.
- 22 Jun 2016 Status changed from recruiting to withdrawn prior to enrolment due to loss of funding support.